SPYRE THERAPEUTICS ($SYRE) posted quarterly earnings results on Tuesday, August 5th. The company reported earnings of -$0.49 per share, beating estimates of -$0.77 by $0.28. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $SYRE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SPYRE THERAPEUTICS Hedge Fund Activity
We have seen 65 institutional investors add shares of SPYRE THERAPEUTICS stock to their portfolio, and 58 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS added 2,392,541 shares (+inf%) to their portfolio in Q1 2025, for an estimated $38,603,649
- TANG CAPITAL MANAGEMENT LLC added 2,050,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $33,076,750
- CITADEL ADVISORS LLC removed 948,423 shares (-87.9%) from their portfolio in Q1 2025, for an estimated $15,302,805
- PARADIGM BIOCAPITAL ADVISORS LP added 600,000 shares (+39.3%) to their portfolio in Q1 2025, for an estimated $9,681,000
- GOLDMAN SACHS GROUP INC removed 550,484 shares (-73.6%) from their portfolio in Q1 2025, for an estimated $8,882,059
- LOGOS GLOBAL MANAGEMENT LP removed 500,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $8,067,500
- BOXER CAPITAL MANAGEMENT, LLC removed 466,680 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $7,529,881
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SPYRE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $SYRE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 04/08/2025
To track analyst ratings and price targets for SPYRE THERAPEUTICS, check out Quiver Quantitative's $SYRE forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
